AzurRx BioPharma Inc News - AZRX

Current Report Filing (8-k)

false0001604191NASDAQ00016041912022-03-312022-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Annual Report (10-k)

false12-312021FY00016041910.10.10.10.10.5http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilit...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252087 PROSPECTUS SUPPLEMENT Dated March 2, 2022 (To Prospectus Dated January...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

TABLE OF CONTENTSFiled Pursuant to Rule 424(b)(5)Registration No. 333-256476PROSPECTUS SUPPLEMENT(To Prospectus Dated June 2...

Current Report Filing (8-k)

false0001604191NASDAQ00016041912022-02-272022-02-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Current Report Filing (8-k)

false0001604191NASDAQ00016041912022-02-142022-02-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:February 02,

Securities Registration Statement (simplified Form) (s-3)

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 21, 2022 Registration No...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy...

Current Report Filing (8-k)

false0001604191NASDAQ00016041912021-12-132021-12-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Current Report Filing (8-k)

false0001604191NASDAQ00016041912021-12-062021-12-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Current Report Filing (8-k)

false0001604191NASDAQ00016041912021-11-262021-11-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

AzurRx BioPharma Inc (AZRX)

Professional-Grade Tools, for Individual Investors.

AZRX News

Current Report Filing (8-k)

Annual Report (10-k)

Initial Statement of Beneficial Ownership (3)

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Current Report Filing (8-k)

Current Report Filing (8-k)

Notice of Effectiveness (effect)

Securities Registration Statement (simplified Form) (s-3)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

AZRX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

AzurRx BioPharma Inc (AZRX) News

AzurRx BioPharma Inc (AZRX)

Professional-Grade Tools, for Individual Investors.

AZRX News

Current Report Filing (8-k)

Annual Report (10-k)

Initial Statement of Beneficial Ownership (3)

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Current Report Filing (8-k)

Current Report Filing (8-k)

Notice of Effectiveness (effect)

Securities Registration Statement (simplified Form) (s-3)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

AZRX Discussion

Your Recent History